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Objective: To explore the use of Diabetes Symptom Checklist-Revised (DSC-R) Cognitive 
Distress, Fatigue, Hyperglycemia, and Hypoglycemia subscales as measures of acute diabetes-
associated symptoms in patients with both type 1 and 2 diabetes.
Research design and methods: Our study was conducted in context of two international, 
multicenter, randomized clinical trials for inhaled insulin. Confirmatory factor analyses and 
assessments of reliability and construct validity were performed.
Results: Study participants were 371 patients with type 2 (56% male; mean age, 57 years) and 
481 with type 1 diabetes (57% male, mean age, 40 years). In both populations a four-factor model 
was the best fit. Cronbach’s α  0.79 and intraclass correlation coefficient 0.63; subscales 
correlated (P  0.05) with measures of well-being and satisfaction (0.12  r  0.71). In patients 
with type 1 diabetes, three subscales correlated (P  0.05) with A1C.
Conclusions: The psychometric properties of the DSC-R Cognitive Distress, Fatigue, 
  Hyperglycemia, and Hypoglycemia suggest they may be utilized in clinical trials as reliable 
and valid measures of acute symptoms of diabetes.
Keywords: Diabetes Symptom Checklist-Revised, DSC-R, type 1 diabetes, type 2 diabetes, 
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Symptoms associated with type 1 and type 2 diabetes include: frequent urination, 
excessive thirst, extreme hunger, unusual weight loss, increased fatigue, irritability, 
and blurry vision.1 These symptoms are indicators of fluctuating blood glucose levels; 
that is, hyperglycemia or hypoglycemia, which can lead to long term complications 
such as kidney or cardiovascular disease and nerve damage.1
The Diabetes Symptoms Checklist Revised (DSC-R) is the revised version of the 
Type 2 Diabetes Symptom Checklist (DSC). Both 34-item measures are designed spe-
cifically to assess the symptom burden of diabetes.2 The original version is structured to 
assess symptom burden by weighting the troublesomeness of symptoms by frequency 
whereas the revised version assesses the of symptoms by frequency asking respond-
ers to reply “yes” or “no” to symptom occurrence followed by a rating of symptom 
troublesomeness. The DSC and DSC-R have both been validated and used extensively 
in type 2 diabetes research to demonstrate relationships between diabetes treatment, 
symptom severity, and health-related quality of life.3–10
Clinical trials evaluating drug therapy for treating diabetes measure A1C, reflecting 
glycemic control over three months, as the primary endpoint. In the context of short dura-Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 28
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tion research (clinical trials), only the acute symptoms resulting 
from fluctuating blood sugars are expected to show immedi-
ate change during this time frame. Therefore, as a means to 
reduce respondent burden in clinical trials, we need to assess 
whether the 15 items of four DSC-R subscales (ie, Cognitive 
Distress, Fatigue, Hyperglycemia, and Hypoglycemia) focused 
on measuring only those acute diabetes-associated symptoms 
could be used as a reliable and valid measure to detect changes 
in those symptoms expected to change in response to initiation 
of antihyperglycemic treatment.
Research design and methods
This study was conducted in context of two international, 
multicenter, randomized clinical trials for an inhaled insulin. 
Study 111 was conducted in insulin-naïve patients with type 2 
diabetes who were poorly controlled by oral anti-hyperglycemic 
treatment. Participants of Study 212 were patients with type 1 
diabetes who were poorly controlled on their current insulin 
regimen.
These studies presented the opportunity to evaluate 
  psychometric properties (factor structure, reliability, validity) of 
the Cognitive Distress (four items), Fatigue (four items), Hyper-
glycemia (four items), and Hypoglycemia (three items) sub-
scales of the DSC-R as a measure of acute diabetes-associated 
symptoms. Both trials were conducted in agreement with the 
Declaration of Helsinki and the International Conference on 
Harmonization, Guidelines to Good Clinical Practice and par-
ticipants signed an informed consent prior to participation.
Participants were administered the 15 items of the DSC-R 
at screening, baseline and six-month study visits. The DSC-R 
items ask respondents to recall the last four weeks and con-
sider each symptom in terms of whether they experienced 
it and if so, how troublesome it was. A response “no” to the 
presence of a symptom equated to the item score 0. Partici-
pants responding “yes” to the presence of a symptom were 
subsequently asked to indicate how troublesome the symp-
tom was on a 5-point scale ranging from “not at all” = 1 to 
“extremely troublesome” = 5. Subscale scores were calcu-
lated by summing item scores and dividing the sum by the 
number of items. Subscale scores range from 0 to 5 with 
higher scores corresponding to greater symptom severity.
Confirmatory factor analysis (CFA) was performed 
on baseline data. Parameter estimates were obtained for 
hypothesized three- and four-factor models. Goodness of fit 
was assessed with the chi-square test and with the fit indices 
of Comparative Fit Index (CFI), Root Mean Square Error 
of Approximation (RMSEA), and Standardized Root Mean 
Residual (SRMR). Maximum likelihood estimation was 
performed, for which a CFI  0.95, and SRMR  0.08 were 
considered indicators of a good fitting model.13
Additional psychometric evaluations: internal reliability 
at baseline using Cronbach’s α; test–retest reliability between 
screening and visit 2 (2 weeks) using intraclass correlation 
coefficient (ICC); responsiveness was calculated as the mean 
difference in scores from baseline to six months divided by 
standard deviation of baseline scores, compared to effect sizes 
of 0.2 (small), 0.5 (medium) and 0.8 (large);14 and Pearson 
correlations between DSC-R subscales and other patient-
reported outcomes (Well-Being Questionnaire-12,15 Diabetes 
Satisfaction Questionnaire16) and A1C at baseline.
Results
Participants who had complete responses for DSC-R items at 
baseline included 371 of 411 randomized patients with type 2 
diabetes (56% male, mean age = 57 years, 62% Caucasian) 
in Study 1, and 481 of 500 randomized patients with type 1 
diabetes (57% male, mean age = 40 years, 65% Caucasian) 
in Study 2 (Table1).
Model fit statistics for study 1 indicated the DSC-R and origi-
nal DSC hypothesized model (four-factor model with Cognitive 
Distress [four items], Fatigue [four items], Hyperglycemia [four 
items], and Hypoglycemia [three items]) fit the data adequately, 
although, modification indices showed that item 3 (sleepiness or 
drowsiness) improved model fit results by loading on the fatigue 
factor, rather than cognitive distress factor, with CFI = 0.96 
and SRMR = 0.038. Factor loadings for all items were 0.62. 
Goodness of model fit in the type 1 diabetes group was similar 
to the type 2 diabetes group with similar factor loadings evident 
across the groups. The internal reliability for the four subscales, 
as dictated by the CFA model, in both populations was 0.79. 
Intraclass correlations were 0.62 (Table 2). A hypothesized 
three-factor model combining cognitive distress and fatigue 
subscales into one psychological subscale (to reflect the origi-
nal DSC structure2,3) was also investigated (results not shown). 
However, study data did not fit the model well.
Changes in A1c from baseline to 6 months were 
observed in Study 1 (mean difference = −0.79%, P  0.001), 
Table 1 Characteristics of study participants
Patients Study 1 (N = 371) Study 2 (N = 481)
Type 2 diabetes Type 1 diabetes
Mean Age (Years) 57 40
Male (%) 56 57
Caucasian (%) 62 65
HbA1c at screening 8.2 ± 1.1% 7.9 ± 1.2%
Abbreviation: HbA1c, glycosylated hemoglobin.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 29
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  responsiveness of DSC-R subscales was demonstrated, mean 
change in score and effect size: Cognitive Distress, −0.1 
(P = 0.06), 0.1; Fatigue, −0.05 (P = 0.36), 0.04; Hyperglyce-
mia, −0.18 (P = 0.001), 0.2, Hypoglycemia, −0.1 (P = 0.07), 
0.1. No changes in A1c were observed in Study 2, therefore, 
responsiveness was not calculated. Significant relationships 
(P  0.05) found in the hypothesized direction between the 
4 DSC-R subscales and well-being and treatment satisfaction 
components (0.12  r  0.71), suggest construct validity. 
Significant, although weak, correlations (P  0.05) with A1C 
were identified for three subscales among the type 1 diabetes 
group (0.12  r  0.14) (Table 2).
Conclusions
The objective of this study was to explore the use of DSC-R 
Cognitive Distress, Fatigue, Hyperglycemia, and Hypoglycemia 
subscales as measures of acute diabetes-associated symptoms 
in patients with type 1 and 2 diabetes. This study suggests that 
the four subscales, with a modified four-factor structure, rather 
than the three-factor structure linking the cognitive distress and 
fatigue subscales as in the original and revised DSC,2,3could be 
utilized as a robust  15-item acute diabetes-associated symptom 
measure.
As demonstrated by previous research utilizing the full 
DSC-R, evidence from this study also substantiates models 
hypothesizing associations between perceived consequences 
of antihyperglycemic treatment with patient’s well-being5,6 as 
well as being one of many drivers of treatment satisfaction.17,18 
As patients perceive symptom severity to decrease the better 
they perceive their well-being or general health which in turn 
results in higher satisfaction in treatment. Patients with type 2 
diabetes tend to report the occurrence of symptoms associated 
with high blood glucose over any other symptom, regardless 
of A1c level,19 which supports responsiveness to change over 
time detected only by the hyperglycemia subscale.
The lack of or low correlation between A1C and symp-
toms may be attributed to differences in measurement peri-
ods as A1C reflects a three-month period of blood glucose 
levels while the DSC-R asks patients to recall and average 
diabetes symptoms over the past four weeks.18 This suggests 
that A1C may not be the most sensitive clinical measure to 
reflect changes in patient symptoms in clinical trial research. 
The more appropriate measures for clinical trials to monitor 
changes in acute symptoms of diabetes over time may be 
fasting blood glucose in addition to the 15-item DSC-R with 
a shortened recall period.
Results of this study represent patients enrolled in a 
clinical trial and may not necessarily be representative of all 
patients with diabetes. Further research evaluating sensitivity 
to change over time, or responsiveness, involving the Cogni-
tive Distress, Fatigue, Hyperglycemia, and Hypoglycemia 
subscales of the DSC-R is recommended. However, as a 
means to reduce respondent burden in clinical trials, this 
study suggests that this 15-item measure is reliable and valid 
in assessing relevant acute symptoms for patients with type 1 
and type 2 diabetes.
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Table 2 Reliability, statistics, and Pearson correlations for DSC-R subscales: cognitive distress, fatigue, hyperglycemia and hypoglycemia
Study 1  
Patients with type 2  
diabetes N = 371
Study 2  
Patients with type 1  
diabetes N = 481
Cognitive 
distress
Fatigue Hyper-
  glycemia
Hypo-
  glycemia
Cognitive 
distress
Fatigue Hyper-
  glycemia
Hypo-
  glycemia
Reliability 
statistics
ICCa 0.76 0.72 0.68 0.73 0.72 0.74 0.62 0.66
Crohnbach’s α 0.91 0.91 0.81 0.83 0.90 0.87 0.82 0.79
Pearson  
correlations
A1C 0.08 0.07 0.13d 0.04 0.07 0.11d 0.14e 0.12d
Positive well-beingb −0.32e −0.39e −0.14e −0.31e −0.37e −0.38e −0.15e −0.33e
Negative well-beingb 0.59e 0.58e 0.32e 0.59e 0.47e 0.46e 0.29e 0.50e
Energyb −0.54e −0.71e −0.32e −0.52e −0.40e −0.61e −0.24e −0.39e
Satisfactionc −0.24e −0.33e −0.12d −0.30e −0.17e −0.21e −0.09 −0.16e
Notes: aICC = Intraclass Correlation Coefficient. Single Measure Consistency; bWell-Being Questionnaire-1210; cDiabetes Satisfaction Questionnaire11; dP  0.05 (2-tailed);   
eP  0.01 (2-tailed).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3
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